Medicus Pharma's SkinJect Therapy Shows Promising Phase 2 Results for Non-Invasive Treatment of Basal Cell Carcinoma.

Medicus Pharma's CEO, Raza Bokhari, discussed promising Phase 2 SkinJect results, highlighting that three out of four treated patients may not require surgical intervention for basal cell carcinoma. The company's microneedle-based therapy, SkinJect, achieved 73% clinical or visual clearance in a 200 microgram cohort. This data supports entering an end-of-Phase 2 meeting with the FDA and accelerates partnering discussions.